Dose escalation by double dosing from 5 to 10 mg/kg for TNF-α inhibitors is common practice in the treatment of IBD for patients who are hypoalbuminemic or do not have an initial response to therapy. The gene discussed is TNF; the disease is inflammatory bowel disease.